国际心血管病杂志
國際心血管病雜誌
국제심혈관병잡지
INTERNATIONAL JOURNAL OF CARDIOVASCULAR DISEASE
2014年
2期
124-126,130
,共4页
胡良巧%薛玉梅%詹贤章%邓海%方咸宏%刘甜%吴书林
鬍良巧%薛玉梅%詹賢章%鄧海%方鹹宏%劉甜%吳書林
호량교%설옥매%첨현장%산해%방함굉%류첨%오서림
心房颤动%替米沙坦%螺内酯%超敏C反应蛋白%N末端B型利钠肽原
心房顫動%替米沙坦%螺內酯%超敏C反應蛋白%N末耑B型利鈉肽原
심방전동%체미사탄%라내지%초민C반응단백%N말단B형리납태원
Atrial fibrillation%Telmisartan%Spironolactone%High-sensitivity C-reactive protein%N terminal pro-brain natriuretic peptide
目的:观察阵发性心房颤动(房颤)患者导管射频消融术后应用替米沙坦联合螺内酯治疗的效果。方法:将90例接受单次射频消融术治疗的阵发性房颤患者随机分为对照组(常规治疗)和研究组(常规治疗+替米沙坦+螺内酯),术后1个月和3个月分别返院复查24 h 动态心电图(Holter)、经胸超声心动图、超敏 C 反应蛋白(hsCRP)及 N 末端 B 型利钠肽原(NT-proBNP)等,并记录房颤复发情况。结果:17例(18.9%)患者术后3个月内再发房颤,其中对照组12例(26.7%),研究组5例(11.1%),两组间差异有统计学意义(P =0.044)。研究组术后3个月 NT-proBNP 明显低于对照组,即(75.9±71.1)pg/ml 对(106.9±74.3)pg/ml,P =0.046;研究组术后3个月 NT-proBNP 与术前的变化量较对照组显著增高,即(-11.13±126.48)pg/ml 对(-59.8±102.30)pg/ml,P =0.037。结论:替米沙坦联合螺内酯治疗能够减少阵发性房颤患者环肺静脉消融术后的早期复发,特别是能够显著降低术后3个月 NT-proBNP 水平。
目的:觀察陣髮性心房顫動(房顫)患者導管射頻消融術後應用替米沙坦聯閤螺內酯治療的效果。方法:將90例接受單次射頻消融術治療的陣髮性房顫患者隨機分為對照組(常規治療)和研究組(常規治療+替米沙坦+螺內酯),術後1箇月和3箇月分彆返院複查24 h 動態心電圖(Holter)、經胸超聲心動圖、超敏 C 反應蛋白(hsCRP)及 N 末耑 B 型利鈉肽原(NT-proBNP)等,併記錄房顫複髮情況。結果:17例(18.9%)患者術後3箇月內再髮房顫,其中對照組12例(26.7%),研究組5例(11.1%),兩組間差異有統計學意義(P =0.044)。研究組術後3箇月 NT-proBNP 明顯低于對照組,即(75.9±71.1)pg/ml 對(106.9±74.3)pg/ml,P =0.046;研究組術後3箇月 NT-proBNP 與術前的變化量較對照組顯著增高,即(-11.13±126.48)pg/ml 對(-59.8±102.30)pg/ml,P =0.037。結論:替米沙坦聯閤螺內酯治療能夠減少陣髮性房顫患者環肺靜脈消融術後的早期複髮,特彆是能夠顯著降低術後3箇月 NT-proBNP 水平。
목적:관찰진발성심방전동(방전)환자도관사빈소융술후응용체미사탄연합라내지치료적효과。방법:장90례접수단차사빈소융술치료적진발성방전환자수궤분위대조조(상규치료)화연구조(상규치료+체미사탄+라내지),술후1개월화3개월분별반원복사24 h 동태심전도(Holter)、경흉초성심동도、초민 C 반응단백(hsCRP)급 N 말단 B 형리납태원(NT-proBNP)등,병기록방전복발정황。결과:17례(18.9%)환자술후3개월내재발방전,기중대조조12례(26.7%),연구조5례(11.1%),량조간차이유통계학의의(P =0.044)。연구조술후3개월 NT-proBNP 명현저우대조조,즉(75.9±71.1)pg/ml 대(106.9±74.3)pg/ml,P =0.046;연구조술후3개월 NT-proBNP 여술전적변화량교대조조현저증고,즉(-11.13±126.48)pg/ml 대(-59.8±102.30)pg/ml,P =0.037。결론:체미사탄연합라내지치료능구감소진발성방전환자배폐정맥소융술후적조기복발,특별시능구현저강저술후3개월 NT-proBNP 수평。
Objective:To clarify the effects of telmisartan combined with spironolactone on early recurrence after catheter ablation in patients with paroxysmal atrial fibrillation (PAF). Methods:A total of 90 patients with PAF treated by catheter ablation were randomly assigned to control group (conventional treatment ) and therapy group (conventional treatment plus telmisartan and spironolactone ). 24h Holter monitoring, echocardiography, high-sensitivity C-reactive protein (hsCRP),and N terminal pro-brain natriuretic peptide (NT-proBNP)were examined at 1 and 3 months. Post-ablation recurrence was also recorded. Results:Post-ablation recurrence was recorded in 5 cases (11 .1 %)in therepy group and 12 cases(26.7%)in control group (P =0.44).Compared with control group,NT-proBNP in therapy group was decreased at 3 months (P =0.046).Variation in NT-proBNP (3 months vs baseline)in therapy group was significantly higher than that in control group (P =0.037). Conclusion:Telmisartan combined with spironolactone reduces early recurrence after catheter ablation of paroxysmal atrial fibrillation,and is associated with a decrease in the level of NT-proBNP at 3 months postoperation.